Report: India Boosting Ability to Regulate Clinical Trials
Posted 10 April 2012 | By
India's regulatory authorities are boosting their ability to enforce regulatory guidelines after years of heightened requirements, reports Outsourcing Pharma.
The Central Drugs Standard Control Organization (CDSCO), which regulates the country's pharmaceutical sector, is seeing an increase in "manpower and infrastructure" to help bring their abilities up their new responsibilities, said Indian Minister of Health and Family Shri Ghulam Nabi Azed.
The Indian pharmaceutical sector has been under heightened scrutiny in recent years. After years of incredible growth after clinical trials restrictions were lifted in 2004, the sector has been hit with news about questionable clinical trials, quality concerns, large fines and patent skirmishes that have spooked western pharmaceutical companies.
CDSCO's announcement also follows one made in January 2012, when Mininister of Science and Technology Vilasrao Deshmukh called for a new emphasis on a "transparent and evidence-based regulatory system."
Outsourcing Pharma - India strengthening clinical trial regulatory capacity, gov says
Regulatory Focus - India's Clinical Trials Attract Patients, Scrutiny
Regulatory Focus - NBC Investigation 'Raises Questions About Lax Regulatory Oversight'
Regulatory Focus - DOJ Files 'Groundbreaking' Consent Decree Against Ranbaxy, Company Agrees to 'Remedy Deviations'
Regulatory Focus - Risk Aversion in Indian Deal-Making the Result of Regulatory Compliance Concerns
Regulatory Focus - In Landmark Ruling, Indian Generics Manufacturer Obtains Compulsory License
Indian Science & Technology Minister Calls for Transparent, Evidence-based Regulatory System